EUVIMEDEUVIMED entdecken
Kohortenstudie

Low Antithrombin III Activity, Nafamostat Monotherapy without Heparin, and Small Filter Size Are Associated with a Shorter Circuit Lifespan in Pediatric Continuous Kidney Replacement Therapy: A Single-Center Retrospective Cohort Study

Kentaro Ide, Yusuke Tokuda, Junichiro Morota, Eisaku Nashiki, Kentaro Nishi, Mai Miyaji, Masamichi Shibata, Shotaro Matsumoto

Blood Purification · 2025

DOI: 10.1159/000549060 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Blood Purification, 2025. Verfasst von Kentaro Ide und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Critical Care Medicine, National Center for Child Health and Development, Setagaya City, Japan, ide-k@ncchd.go.jp. Hauptthemen laut MEDLINE: Guanidines, Antithrombin III, Continuous Renal Replacement Therapy. Die Arbeit nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Premature circuit clotting remains a major limitation of pediatric continuous kidney replacement therapy (CKRT). While anticoagulation with heparin or citrate has been well studied, the risk factors for circuit failure under nafamostat mesylate (NM) use have not been well characterized.

Methods

This retrospective cohort study included pediatric patients aged

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GuanidinesAntithrombin IIIContinuous Renal Replacement TherapyHumansRetrospective StudiesMaleFemaleChildChild, PreschoolHeparinBenzamidinesInfantAdolescentAnticoagulantsRisk Factors

Stichwörter der Autor:innen

Antithrombin IIIChildrenCircuit survivalContinuous kidney replacement therapyFilter lifespan

Substanzen

nafamostatGuanidinesHeparinBenzamidinesAntithrombin IIIAnticoagulants

Autor:innen und Institutionen

  • Division of Critical Care Medicine, National Center for Child Health and Development, Setagaya City, Japan, ide-k@ncchd.go.jp.
  • Division of Critical Care Medicine, National Center for Child Health and Development, Setagaya City, Japan.
  • Division of Nephrology and Rheumatology, National Center for Child Health and Development, Setagaya City, Japan.
  • Pediatric Intensive Care Unit, Department of Pediatrics, St. Marianna University School of Medicine, Kawasaki, Japan.
  • Division of Clinical Engineering, National Center for Child Health and Development, Setagaya City, Japan.

Zitieren

APA

Ide, K., Tokuda, Y., Morota, J., Nashiki, E., Nishi, K., Miyaji, M., Shibata, M., & Matsumoto, S. (2025). Low Antithrombin III Activity, Nafamostat Monotherapy without Heparin, and Small Filter Size Are Associated with a Shorter Circuit Lifespan in Pediatric Continuous Kidney Replacement Therapy: A Single-Center Retrospective Cohort Study. Blood Purification. https://doi.org/10.1159/000549060

Vancouver

Ide K, Tokuda Y, Morota J, Nashiki E, Nishi K, Miyaji M, et al. Low Antithrombin III Activity, Nafamostat Monotherapy without Heparin, and Small Filter Size Are Associated with a Shorter Circuit Lifespan in Pediatric Continuous Kidney Replacement Therapy: A Single-Center Retrospective Cohort Study. Blood Purification. 2025. doi:10.1159/000549060

BibTeX
@article{Ide2025,
  author = {Ide, Kentaro and Tokuda, Yusuke and Morota, Junichiro and Nashiki, Eisaku and Nishi, Kentaro and Miyaji, Mai and Shibata, Masamichi and Matsumoto, Shotaro},
  title = {Low Antithrombin III Activity, Nafamostat Monotherapy without Heparin, and Small Filter Size Are Associated with a Shorter Circuit Lifespan in Pediatric Continuous Kidney Replacement Therapy: A Single-Center Retrospective Cohort Study},
  journal = {Blood Purification},
  year = {2025},
  doi = {10.1159/000549060}
}
Kostenlos starten →